Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease (MyRIAD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02121028 |
Recruitment Status :
Active, not recruiting
First Posted : April 23, 2014
Last Update Posted : January 15, 2021
|
Tracking Information | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date | April 18, 2014 | |||||||||
First Posted Date | April 23, 2014 | |||||||||
Last Update Posted Date | January 15, 2021 | |||||||||
Actual Study Start Date | January 2015 | |||||||||
Actual Primary Completion Date | December 31, 2020 (Final data collection date for primary outcome measure) | |||||||||
Current Primary Outcome Measures |
Recurrent stroke in the territory of the symptomatic artery [ Time Frame: 1 year ] Time to ischemic stroke in the territory of the symptomatic artery. Stroke is ascertained by the site neurologist and defined as new or worsening symptoms lasting >24 hours and associated with imaging evidence of ischemia on CT or MRI in the distribution of the stenotic artery.
|
|||||||||
Original Primary Outcome Measures | Same as current | |||||||||
Change History | ||||||||||
Current Secondary Outcome Measures |
|
|||||||||
Original Secondary Outcome Measures |
|
|||||||||
Current Other Pre-specified Outcome Measures |
|
|||||||||
Original Other Pre-specified Outcome Measures | Same as current | |||||||||
Descriptive Information | ||||||||||
Brief Title | Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease | |||||||||
Official Title | Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease | |||||||||
Brief Summary | The objective of this study is to determine the mechanisms of stroke in patients with Intracranial Atherosclerotic Disease (IAD) by specifically evaluating limitations of antegrade flow through the stenotic artery, distal tissue perfusion to the affected territory, and artery-to-artery embolism. The hypothesis is that non-invasive imaging biomarkers that stratify stroke risk and distinguish mechanisms of IAD. This prospective multicenter study will enroll 175 patients with recently symptomatic high-grade IAD. Patients will be studied within 21 days of the index event (allowing appropriate time to arrange for diverse imaging modalities), with the following advanced neuroimaging techniques to elucidate mechanisms of recurrent ischemia:
Patients will receive standardized medical management and its effectiveness on blood pressure, lipid, and glycemic control will be monitored. The primary outcome is recurrent stroke in the territory of the stenotic artery during a 1-year follow-up period; secondary outcomes are: a) new asymptomatic ischemic lesions on MRI in the distribution of the stenotic artery at 6-8 weeks, and b) transient ischemic attack (TIA) in the distribution of the stenotic artery during a 1-year follow-up period. Patients will be recruited at various sites that will be trained and certified on the imaging techniques employed. Raw imaging data will be interpreted centrally. |
|||||||||
Detailed Description | Not Provided | |||||||||
Study Type | Observational | |||||||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
|||||||||
Target Follow-Up Duration | Not Provided | |||||||||
Biospecimen | Not Provided | |||||||||
Sampling Method | Non-Probability Sample | |||||||||
Study Population | Eligible patients will have a recent stroke or TIA due to intracranial Atherosclerotic Disease (IAD) of 50-99% . | |||||||||
Condition | Intracranial Vascular Disorders | |||||||||
Intervention | Not Provided | |||||||||
Study Groups/Cohorts | Intracranial Atherosclerotic Disease, Stroke/TIA
Stroke/TIA due to high grade IAD ≤21 days from symptom onset.
|
|||||||||
Publications * | Romano JG, Prabhakaran S, Nizam A, Feldmann E, Sangha R, Cotsonis G, Campo-Bustillo I, Koch S, Rundek T, Chimowitz MI, Liebeskind DS; MyRIAD Investigators. Infarct recurrence in intracranial atherosclerosis: Results from the MyRIAD study. J Stroke Cerebrovasc Dis. 2020 Dec 1;30(2):105504. doi: 10.1016/j.jstrokecerebrovasdis.2020.105504. [Epub ahead of print] | |||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
||||||||||
Recruitment Information | ||||||||||
Recruitment Status | Active, not recruiting | |||||||||
Estimated Enrollment |
175 | |||||||||
Original Estimated Enrollment | Same as current | |||||||||
Estimated Study Completion Date | August 31, 2021 | |||||||||
Actual Primary Completion Date | December 31, 2020 (Final data collection date for primary outcome measure) | |||||||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
|||||||||
Sex/Gender |
|
|||||||||
Ages | 30 Years to 99 Years (Adult, Older Adult) | |||||||||
Accepts Healthy Volunteers | No | |||||||||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||||||||
Listed Location Countries | United States | |||||||||
Removed Location Countries | ||||||||||
Administrative Information | ||||||||||
NCT Number | NCT02121028 | |||||||||
Other Study ID Numbers | 20140056 1R01NS084288-01A1 ( U.S. NIH Grant/Contract ) |
|||||||||
Has Data Monitoring Committee | No | |||||||||
U.S. FDA-regulated Product |
|
|||||||||
IPD Sharing Statement |
|
|||||||||
Responsible Party | Jose Romano, MD, University of Miami | |||||||||
Study Sponsor | University of Miami | |||||||||
Collaborators |
|
|||||||||
Investigators |
|
|||||||||
PRS Account | University of Miami | |||||||||
Verification Date | January 2021 |